Efficacy of omeprazole in functional dyspepsia : double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)
Identifieur interne : 000C31 ( PascalFrancis/Curation ); précédent : 000C30; suivant : 000C32Efficacy of omeprazole in functional dyspepsia : double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)
Auteurs : N. J. Talley [Australie] ; V. Meineche-Schmidt [Australie] ; P. Pare [Australie] ; M. Duckworth [Australie] ; P. R Is Nen [Australie] ; A. Pap [Australie] ; H. Kordecki [Australie] ; V. Schmid [Australie]Source :
- Alimentary pharmacology & therapeutics [ 0269-2813 ] ; 1998.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Background: The efficacy of H2-receptor antagonists in functional dyspepsia is equivocal and the therapeutic place of proton pump inhibitors in functional dyspepsia is unknown. Aim: To evaluate the efficacy of proton pump inhibitor therapy in functional dyspepsia. Methods; Patients (n = 1262) with a clinical diagnosis of functional dyspepsia (persistent or recurrent epigastric pain or discomfort for at least 1 month and a normal upper gastrointestinal endoscopy) were randomized to receive omeprazole 20 mg. 10 mg or identical placebo, for 4 weeks. Symptoms were assessed using validated measures. Helicobacter pylori status was determined pre-entry by a 13C-urea breath test. Results: On an intention-to-treat analysis (n=1248). complete symptom relief was observed in 38% on omeprazole 20 mg, compared with 36% on omeprazole 10 mg and 28% on placebo (P = 0.002 and 0.02. respectively). Among those with ulcer-like and reflux-like dyspepsia, complete symptom relief was achieved in 40% and 54% on omeprazole 20 mg, and 35% and 45% on omeprazole 10 mg, respectively, compared with 27% and 23% on placebo (all P < 0.05, except omeprazole 10 mg in ulcer-like dyspepsia. P = 0.08). There was no significant benefit of omeprazole over placebo in dysmotility-like dyspepsia. Symptom relief was similar in H. pylori-positive and negative cases. Conclusions: Omeprazole is modestly superior to placebo in functional dyspepsia at standard (20 mg) and low doses (10 mg) but not in patients with dysmotility-like dyspepsia.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000805
Links to Exploration step
Pascal:99-0043793Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Efficacy of omeprazole in functional dyspepsia : double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)</title><author><name sortKey="Talley, N J" sort="Talley, N J" uniqKey="Talley N" first="N. J." last="Talley">N. J. Talley</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Meineche Schmidt, V" sort="Meineche Schmidt, V" uniqKey="Meineche Schmidt V" first="V." last="Meineche-Schmidt">V. Meineche-Schmidt</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Pare, P" sort="Pare, P" uniqKey="Pare P" first="P." last="Pare">P. Pare</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Duckworth, M" sort="Duckworth, M" uniqKey="Duckworth M" first="M." last="Duckworth">M. Duckworth</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="R Is Nen, P" sort="R Is Nen, P" uniqKey="R Is Nen P" first="P." last="R Is Nen">P. R Is Nen</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Pap, A" sort="Pap, A" uniqKey="Pap A" first="A." last="Pap">A. Pap</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Kordecki, H" sort="Kordecki, H" uniqKey="Kordecki H" first="H." last="Kordecki">H. Kordecki</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Schmid, V" sort="Schmid, V" uniqKey="Schmid V" first="V." last="Schmid">V. Schmid</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">99-0043793</idno><date when="1998">1998</date><idno type="stanalyst">PASCAL 99-0043793 INIST</idno><idno type="RBID">Pascal:99-0043793</idno><idno type="wicri:Area/PascalFrancis/Corpus">000805</idno><idno type="wicri:Area/PascalFrancis/Curation">000C31</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Efficacy of omeprazole in functional dyspepsia : double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)</title><author><name sortKey="Talley, N J" sort="Talley, N J" uniqKey="Talley N" first="N. J." last="Talley">N. J. Talley</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Meineche Schmidt, V" sort="Meineche Schmidt, V" uniqKey="Meineche Schmidt V" first="V." last="Meineche-Schmidt">V. Meineche-Schmidt</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Pare, P" sort="Pare, P" uniqKey="Pare P" first="P." last="Pare">P. Pare</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Duckworth, M" sort="Duckworth, M" uniqKey="Duckworth M" first="M." last="Duckworth">M. Duckworth</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="R Is Nen, P" sort="R Is Nen, P" uniqKey="R Is Nen P" first="P." last="R Is Nen">P. R Is Nen</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Pap, A" sort="Pap, A" uniqKey="Pap A" first="A." last="Pap">A. Pap</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Kordecki, H" sort="Kordecki, H" uniqKey="Kordecki H" first="H." last="Kordecki">H. Kordecki</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Schmid, V" sort="Schmid, V" uniqKey="Schmid V" first="V." last="Schmid">V. Schmid</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author></analytic><series><title level="j" type="main">Alimentary pharmacology & therapeutics</title><title level="j" type="abbreviated">Aliment. pharmacol. ther.</title><idno type="ISSN">0269-2813</idno><imprint><date when="1998">1998</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Alimentary pharmacology & therapeutics</title><title level="j" type="abbreviated">Aliment. pharmacol. ther.</title><idno type="ISSN">0269-2813</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antisecretory agent</term><term>Antiulcer agent</term><term>Benzimidazole derivatives</term><term>Chemotherapy</term><term>Controlled therapeutic trial</term><term>Double blind study</term><term>Dyspepsia</term><term>Helicobacter pylori</term><term>Human</term><term>Long term</term><term>Omeprazole</term><term>Placebo</term><term>Proton pump inhibitor</term><term>Randomization</term><term>Treatment</term><term>Treatment efficiency</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Oméprazole</term><term>Antiulcéreux</term><term>Antisécrétoire</term><term>Chimiothérapie</term><term>Traitement</term><term>Dyspepsie</term><term>Homme</term><term>Essai thérapeutique contrôlé</term><term>Etude double insu</term><term>Randomisation</term><term>Placebo</term><term>Inhibiteur pompe proton</term><term>Long terme</term><term>Efficacité traitement</term><term>Helicobacter pylori</term><term>Benzimidazole dérivé</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: The efficacy of H<sub>2</sub>-receptor antagonists in functional dyspepsia is equivocal and the therapeutic place of proton pump inhibitors in functional dyspepsia is unknown. Aim: To evaluate the efficacy of proton pump inhibitor therapy in functional dyspepsia. Methods; Patients (n = 1262) with a clinical diagnosis of functional dyspepsia (persistent or recurrent epigastric pain or discomfort for at least 1 month and a normal upper gastrointestinal endoscopy) were randomized to receive omeprazole 20 mg. 10 mg or identical placebo, for 4 weeks. Symptoms were assessed using validated measures. Helicobacter pylori status was determined pre-entry by a <sup>13</sup>C-urea breath test. Results: On an intention-to-treat analysis (n=1248). complete symptom relief was observed in 38% on omeprazole 20 mg, compared with 36% on omeprazole 10 mg and 28% on placebo (P = 0.002 and 0.02. respectively). Among those with ulcer-like and reflux-like dyspepsia, complete symptom relief was achieved in 40% and 54% on omeprazole 20 mg, and 35% and 45% on omeprazole 10 mg, respectively, compared with 27% and 23% on placebo (all P < 0.05, except omeprazole 10 mg in ulcer-like dyspepsia. P = 0.08). There was no significant benefit of omeprazole over placebo in dysmotility-like dyspepsia. Symptom relief was similar in H. pylori-positive and negative cases. Conclusions: Omeprazole is modestly superior to placebo in functional dyspepsia at standard (20 mg) and low doses (10 mg) but not in patients with dysmotility-like dyspepsia.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0269-2813</s0></fA01><fA03 i2="1"><s0>Aliment. pharmacol. ther.</s0></fA03><fA05><s2>12</s2></fA05><fA06><s2>11</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Efficacy of omeprazole in functional dyspepsia : double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)</s1></fA08><fA11 i1="01" i2="1"><s1>TALLEY (N. J.)</s1></fA11><fA11 i1="02" i2="1"><s1>MEINECHE-SCHMIDT (V.)</s1></fA11><fA11 i1="03" i2="1"><s1>PARE (P.)</s1></fA11><fA11 i1="04" i2="1"><s1>DUCKWORTH (M.)</s1></fA11><fA11 i1="05" i2="1"><s1>RÄISÄNEN (P.)</s1></fA11><fA11 i1="06" i2="1"><s1>PAP (A.)</s1></fA11><fA11 i1="07" i2="1"><s1>KORDECKI (H.)</s1></fA11><fA11 i1="08" i2="1"><s1>SCHMID (V.)</s1></fA11><fA14 i1="01"><s1>Department of Medicine, University of Sydney, Nepean Hospital</s1><s2>Penrith, New South Wales</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></fA14><fA20><s1>1055-1065</s1></fA20><fA21><s1>1998</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>21831</s2><s5>354000071760440020</s5></fA43><fA44><s0>0000</s0><s1>© 1999 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>38 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>99-0043793</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i2="1"><s0>Alimentary pharmacology & therapeutics</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: The efficacy of H<sub>2</sub>-receptor antagonists in functional dyspepsia is equivocal and the therapeutic place of proton pump inhibitors in functional dyspepsia is unknown. Aim: To evaluate the efficacy of proton pump inhibitor therapy in functional dyspepsia. Methods; Patients (n = 1262) with a clinical diagnosis of functional dyspepsia (persistent or recurrent epigastric pain or discomfort for at least 1 month and a normal upper gastrointestinal endoscopy) were randomized to receive omeprazole 20 mg. 10 mg or identical placebo, for 4 weeks. Symptoms were assessed using validated measures. Helicobacter pylori status was determined pre-entry by a <sup>13</sup>C-urea breath test. Results: On an intention-to-treat analysis (n=1248). complete symptom relief was observed in 38% on omeprazole 20 mg, compared with 36% on omeprazole 10 mg and 28% on placebo (P = 0.002 and 0.02. respectively). Among those with ulcer-like and reflux-like dyspepsia, complete symptom relief was achieved in 40% and 54% on omeprazole 20 mg, and 35% and 45% on omeprazole 10 mg, respectively, compared with 27% and 23% on placebo (all P < 0.05, except omeprazole 10 mg in ulcer-like dyspepsia. P = 0.08). There was no significant benefit of omeprazole over placebo in dysmotility-like dyspepsia. Symptom relief was similar in H. pylori-positive and negative cases. Conclusions: Omeprazole is modestly superior to placebo in functional dyspepsia at standard (20 mg) and low doses (10 mg) but not in patients with dysmotility-like dyspepsia.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02H</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Oméprazole</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Omeprazole</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Omeprazol</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Antiulcéreux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Antiulcer agent</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Antiulceroso</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Antisécrétoire</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Antisecretory agent</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Antisecretorio</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0><s5>07</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0><s5>07</s5></fC03><fC03 i1="05" i2="X" l="GER"><s0>Aufbereiten</s0><s5>07</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0><s5>07</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Dyspepsie</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Dyspepsia</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Dispepsia</s0><s5>10</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Human</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Essai thérapeutique contrôlé</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Controlled therapeutic trial</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Ensayo terapéutico controlado</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Etude double insu</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Double blind study</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Estudio doble ciego</s0><s5>14</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Randomisation</s0><s5>16</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Randomization</s0><s5>16</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Aleatorización</s0><s5>16</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Placebo</s0><s5>18</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Placebo</s0><s5>18</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Placebo</s0><s5>18</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Inhibiteur pompe proton</s0><s5>19</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Proton pump inhibitor</s0><s5>19</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Inhibidor bomba protón</s0><s5>19</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Long terme</s0><s5>20</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Long term</s0><s5>20</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Largo plazo</s0><s5>20</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Efficacité traitement</s0><s5>21</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Treatment efficiency</s0><s5>21</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Eficacia tratamiento</s0><s5>21</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Helicobacter pylori</s0><s2>NS</s2><s5>22</s5></fC03><fC03 i1="15" i2="X" l="ENG"><s0>Helicobacter pylori</s0><s2>NS</s2><s5>22</s5></fC03><fC03 i1="15" i2="X" l="SPA"><s0>Helicobacter pylori</s0><s2>NS</s2><s5>22</s5></fC03><fC03 i1="16" i2="X" l="FRE"><s0>Benzimidazole dérivé</s0><s2>FR</s2><s2>FF</s2><s5>25</s5></fC03><fC03 i1="16" i2="X" l="ENG"><s0>Benzimidazole derivatives</s0><s2>FR</s2><s2>FF</s2><s5>25</s5></fC03><fC03 i1="16" i2="X" l="SPA"><s0>Benzimidazol derivado</s0><s2>FR</s2><s2>FF</s2><s5>25</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Spirillaceae</s0><s2>NS</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Spirillaceae</s0><s2>NS</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Spirillaceae</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Spirillales</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Spirillales</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Spirillales</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Bactérie</s0></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Bacteria</s0></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Bacteria</s0></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Appareil digestif pathologie</s0><s5>61</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Digestive diseases</s0><s5>61</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Aparato digestivo patología</s0><s5>61</s5></fC07><fN21><s1>025</s1></fN21></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C31 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000C31 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:99-0043793
|texte= Efficacy of omeprazole in functional dyspepsia : double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)
}}
| This area was generated with Dilib version V0.6.21. |  |